ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > I'm in the Red

<< Previous

Bullboard Posts

Next >>

Comment by Mole101on Nov 22, 2021 4:26pm

139 Views

Post# 34154459

RE:RE:I'm in the Red

incomplete chart (sorry!)

House 001

Anonymous

Bought	$239,952
Volume	1,363,426
Average	$0.176

Sold	$761,816
Volume	4,352,681
Average	$0.175

Net	$-521,864
Volume	-2,989,255

Mole101 wrote:

I wouldn't be surprised to see a lower sp . The reality is that they are pocketing all those sold shares and at the same time they justify that 60 to 1 consolidation.

House Positions for PMN.TO

Include ATS trades
From: To:

8,811,201 ($1,545,075) PMN.TO shares exchanged hands from Fri Oct 22 2021 to Mon Nov 22 2021.

House Bought Sold Net

House 022

Fidelity

Bought $469,539

Volume 2,684,000

Average $0.175

Sold $2,740

Volume 15,500

Average $0.177

Net $466,799

Volume 2,668,500

House 009

BMO Nesbitt

Bought $230,516

Volume 1,309,800

Average $0.176

Sold $67,410

Volume 363,439

Average $0.185

Net $163,106

Volume 946,361

House 083

Mackie

Bought $62,721

Volume 356,000

Average $0.176

Sold $3,500

Volume 20,000

Average $0.175

Net $59,221

Volume 336,000

House 002

RBC

Bought $191,859

Volume 1,102,588

Average $0.174

Sold $151,625

Volume 857,121

Average $0.177

Net $40,234

Volume 245,467

House 065

Goldman

Bought $18,022

Volume 100,000

Average $0.180

Sold 0

Volume 0

Average 0

Net $18,022

Volume 100,000

House 080

National Bank

Bought $87,985

Volume 478,760

Average $0.184

Sold $68,185

Volume 384,205

Average $0.177

Net $19,800

Volume 94,555

House 039

Merrill Lynch

Bought $13,798

Volume 78,729

Average $0.175

Sold $12,057

Volume 69,074

Average $0.175

Net $1,741

Volume 9,655

House 059

PI

Bought 0

Volume 0

Average 0

Sold $47

Volume 265

Average $0.177

Net $-47

Volume -265

House 124

Questrade

Bought $3,869

Volume 21,660

Average $0.179

Sold $3,968

Volume 22,600

Average $0.176

Net $-99

Volume -940

House 084

Ind Trading

Bought $95

Volume 500

Average $0.190

Sold $314

Volume 1,769

Average $0.178

Net $-219

Volume -1,269

House 094

Hampton

Bought 0

Volume 0

Average 0

Sold $259

Volume 1,400

Average $0.185

Net $-259

Volume -1,400

House 028

BBS

Bought 0

Volume 0

Average 0

Sold $925

Volume 5,000

Average $0.185

Net $-925

Volume -5,000

House 055

Velocity

Bought 0

Volume 0

Average 0

Sold $1,183

Volume 6,574

Average $0.180

Net $-1,183

Volume -6,574

House 143

Pershing

Bought 0

Volume 0

Average 0

Sold $1,683

Volume 9,570

Average $0.176

Net $-1,683

Volume -9,570

House 089

Raymond James

Bought 0

Volume 0

Average 0

Sold $1,935

Volume 10,727

Average $0.180

Net $-1,935

Volume -10,727

House 019

Desjardins

Bought $635

Volume 3,600

Average $0.176

Sold $3,225

Volume 18,500

Average $0.174

Net $-2,590

Volume -14,900

House 088

Credential

Bought $1,810

Volume 11,000

Average $0.165

Sold $7,733

Volume 42,915

Average $0.180

Net $-5,923

Volume -31,915

House 085

Scotia

Bought $31,795

Volume 174,050

Average $0.183

Sold $38,422

Volume 213,664

Average $0.180

Net $-6,627

Volume -39,614

House 014

ITG

Bought $1,540

Volume 9,000

Average $0.171

Sold $9,790

Volume 56,500

Average $0.173

Net $-8,250

Volume -47,500

House 033

Canaccord

Bought $36,640

Volume 212,283

Average $0.173

Sold $47,675

Volume 271,658

Average $0.175

Net $-11,035

Volume -59,375

House 057

Interactive

Bought 0

Volume 0

Average 0

Sold $16,436

Volume 94,000

Average $0.175

Net $-16,436

Volume -94,000

House 013

Instinet

Bought $28,380

Volume 162,000

Average $0.175

Sold $55,174

Volume 312,500

Average $0.177

Net $-26,794

Volume -150,500

House 079

CIBC

Bought $17,325

Volume 106,550

Average $0.163

Sold $57,380

Volume 324,400

Average $0.177

Net $-40,055

Volume -217,850

House 053

Morgan Stanley

Bought $3,192

Volume 18,000

Average $0.177

Sold $47,651

Volume 272,000

Average $0.175

Net $-44,459

Volume -254,000

House 007

TD Sec

Bought $105,402

Volume 619,255

Average $0.170

Sold $183,942

Volume 1,085,144

Average $0.170

Net $-78,540

Volume -465,889

House 001

Anonymous

Bought $239,952

Volume 1,363,426

Average $0.176

DavidKingCanada wrote: Well it's not looking to good on the current Shareholders, price is falling as we speak.
I believe there will be some PR before the Consolidation occurs which we may see a few points upwards, some can Sell at this point. As for others, post-consolidation may increase the SP but without any Plan going forward we may even see further decrease in SP.
Curious as to what others are doing, it seems like alot of people of Selling at losses. I don't mind being not able to sell as I don't need the Money right now.